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Abstract
Introduction: Pulmonary Arterial Hypertension (PAH) is a progressively devastating disease characterized by excessive
proliferation of the Pulmonary Arterial Smooth Muscle Cells (PASMCs). Studies suggest that PAH and cancers share an
apoptosis-resistant state featuring excessive cell proliferation. The proliferation of cancer cells is mediated by increased
expression of Enhancer of Zeste Homolog 2 (EZH2), a mammalian histone methyltransferase that contributes to the
epigenetic silencing of target genes. However, the role of EZH2 in PAH has not been studied. In this study, it is hypothesized
that EZH2 could play a role in the proliferation of PASMCs.
Methods: In the present study, the expression patterns of EZH2 were investigated in normal and hypertensive mouse
PASMCs. The effects of EZH2 overexpression on the proliferation of human PASMCs were tested. PASMCs were transfected
with EZH2 or GFP using nucleofector system. After transfection, the cells were incubated for 48 hours at 37uC. Proliferation
and cell cycle analysis were performed using flow cytometry. Apoptosis of PASMCs was determined using annexin V
staining and cell migration was tested by wound healing assay.
Results: EZH2 protein expression in mouse PASMCs were correlated with an increase in right ventricular systolic pressure
and Right Ventricular Hypertrophy (RVH). The overexpression of EZH2 in human PASMCs enhances proliferation, migration,
and decrease in the rate of apoptosis when compared to GFP-transfected cells. In the G2/M phase of the EZH2 transfected
cells, there was a 3.5 fold increase in proliferation, while there was a significant decrease in the rate of apoptosis of PASMCs,
when compared to control.
Conclusion: These findings suggest that EZH2 plays a role in the migration and proliferation of PASMCs, which is a major
hallmark in PAH. It also suggests that EZH2 could play a role in the development of PAH and can serve as a potential target
for new therapies for PAH.
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Introduction
Pulmonary Arterial Hypertension (PAH) is a hemodynamic
condition in which one or more of the pulmonary vasculature is
affected and the mean pulmonary arterial pressure and pulmonary
vascular resistance are elevated [1][2,3]. It afflicts approximately
100,000 individuals and causes 20,000 deaths annually in the
United States [4]. PAH is characterized by an excessive
proliferation of the Pulmonary Artery Smooth Muscle Cells
(PASMCs), the diseased Pulmonary Arteries (PA) in PAH are
characterized by vasoconstriction, suppressed apoptosis and
increased proliferation within the vascular wall [5,6]. The
underlying causes or genetic factors responsible for the proproli-
ferative and antiapoptotic properties of PASMCs in PAH are not
clear [1][3][2]. Endothelial dysfunction, an early abnormality in
PAH, leads to an increase in vasoconstrictors like endothelin over
vasodilators like prostacyclin [1]. Correction of these abnormalities
by blockade of the endothelin axis or enhancement of the
prostacyclin axis is the basis of the current treatment for PAH;
however the morbidity and mortality remains high [7]. More
effective therapies for PAH will have to directly and selectively
target the mechanisms leading to the proproliferative and
antiapoptotic environment in the vascular wall.
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The idea that hypoxia alone can cause pulmonary hypertension
and significant structural remodeling of pulmonary arteries (PAs)
in humans is supported by observations that humans living at high
altitudes developed an elevated pulmonary arterial (PA) pressure.
Only a small portion is reversible with oxygen [9]. A far greater
increase in PA pressure is observed in high altitude versus sea-level
residents in response to exercise [8,9]. Likewise, volunteers were
exposed to decreased levels of hypobaric hypoxia over 6-weeks.
After 40 days, pulmonary arterial pressures were higher in these
hypoxemia subjects [10,11]. There was a lack of vasodilator
response to the acute administration of 100% oxygen in these
subjects indicating that significant structural remodeling in the
pulmonary vascular bed occurs over this relatively short time
[8,11]. These studies show the importance of chronic hypoxia as a
contributing factor in PAH. Therefore, a well-defined hypoxia
induced PAH mouse model was utilized in these studies.
Cancer and PAH cells share an apoptosis-resistant and
proliferating phenotype [12], and epigenetic gene silencing could
be a major factor in the progression of some forms of cancer [13].
Enhancer of zeste homolog 2 (EZH2) is a mammalian histone
methyltransferase that contributes to the epigenetic silencing of
target genes through methylation and promotes proliferation and
metastasis of cancer cells. EZH2 expression and methylation status
are known to be predictive of the progression and treatment
outcomes of certain cancers [14][15]. Abnormal methylation has
been suggested to be associated with cardiovascular pulmonary
diseases [16]. However, until now, the role of EZH2 in
cardiovascular and pulmonary diseases has not been documented.
Since excessive cell proliferation is a common feature of PAH
and some cancers, it is hypothesized that EZH2 plays a role in the
proliferation of pulmonary arterial smooth muscle Cells (PASMCs)
in PAH. This report is the first investigation focused on exploring
the role of EZH2 in PAH. Our results show that the levels of
EZH2 are induced in hypoxia-mediated PAH mice and that
overexpression of EZH2 modulates proliferation, migration and
resistance to apoptosis of PASMCs, all of which are known to be
hallmarks in the pathogenesis of PAH.
Materials and Methods
Cells and cell culture
Human PASMCS (HPASMCs) were purchased (Cascade
Biologics, Portland, OR) and maintained in growth media
M231(Invitrogen, Carlsbad, CA) supplemented with Smooth
Muscle Growth Supplement (SMGS) (Invitrogen, Carlsbad, CA)
at 37uCi n5 %C O 2 as described in earlier studies [17].
Hypoxia exposure
Approval of the study protocol was obtained from the
Massachusetts General Hospital Institutional Animal Care and
Use Committee with protocol number A3596-01. All mice were
maintained in a specific-pathogen-free animal facility at Massa-
chusetts General Hospital and all animal experiments were carried
out according to the provisions of the Animal Welfare Act, PHS
Animal Welfare Policy, and the principles of the NIH Guide for
the Care and Use of Laboratory Animals. Five age and sex-
matched C57BL/6 mice were exposed to room air (21% FiO2) or
hypoxia (10% FiO2) at sea level. All animals were 3 months old
and weighed 22.562.0 grams. Mice were housed in a sealed
chamber, and the O2 concentration maintained at 10% by
controlling the inflow rate of compressed air and N2. The CO2
concentration was maintained at ,0.4% with a CO2 absorbent.
Gas samples were tested twice per day during the entire
experimental period to monitor O2 and CO2 tension. The
chamber was unsealed for less than 30 minutes twice per week
to replenish food, replace CO2 absorbent and clean the cages as
described [18].
Measurement of right ventricular systolic pressure (RVSP)
Mice hemodynamic measurements were performed as previ-
ously described [18] to assess the right ventricular hypertrophy.
The right ventricle was dissected from the left ventricle and
interventricular septum was weighed separately, and the weight
ratio was calculated as the ratio of weight of the right ventricle to
that of the left ventricle plus the interventricular septum as
described in earlier studies [18].
Isolation of mouse PASMCs
Mouse PASMCs were derived from pulmonary arterioles using
an iron oxide magnetic separation method as previously described
[19,20]. Ten mice were used for each group to isolate PASMCs.
HPASMC proliferation assay
The proliferation of HPASMCs was assessed by flow cytometry
as previously described [15,17]. Briefly, the cell pellet was re-
suspended in 200 mL of PBS and then transferred to a cold vial of
methanol (80 mL) and vortexed immediately. Cells were kept in
methanol at 4uC overnight for fixing. The cells were resuspended
in buffer containing 50 mL PBS, 3.3 mL RNAse (30 mg/mL) and
the mixture was incubated at 4uC for 5 minutes. 450 mL of FACS
buffer (PBS+2% fetal bovine serum) and 25 mL of propidium
iodide (PI,1 mg/mL) were then added. The cells were analyzed
using flow cytometry following 30 minute incubation at room
temperature.
Annexin V staining
An annexin V-FITC assay (BD Biosciences Pharmingen, San
Jose, CA, USA) was performed as per the manufacturer
instructions. The cells were incubated in the presence of annexin
V-FITC and PI for 15 min at 37uC. The labeled cells were
analyzed by flow cytometry as described in earlier studies [21].
Wound healing assay
Wound healing assay and migration were performed as
described in previous studies [15]. Briefly, an artificial wound
was created using a 1 ml pipette tip on confluent HPASMCs
monolayer. Flourescent images were taken at 0 and 24 hrs to
visualize migrated cells and wound healing. The number of cells
migrating into the wound area was counted and compared
between EZH2 and vehicle transfected cells as described [22].
EZH2 Transfection
PASMCs were transfected using the 4D-Nucleofector system
according to the manufacturer’s protocol from Lonza (Walkers-
ville, MD). HPASMCs were cultured until they reached a
confluency of 70% and then transfected with a total of 4 mgo f
plasmid DNA. Transfection efficiency was determined after
48 hours of transfection by both real-time PCR and western blot
analysis for EZH2.
SDS-PAGE and Western blotting
HPASMCs were harvested, washed twice with ice-cold PBS and
lysed with ice-cold RIPA lysis buffer (PBS, 1% NP40, 0.5%
sodium deoxycholate, 0.1% SDS, 1 mM PMSF, 10 mg/ml
leupeptin, and 1 mM sodium orthovanadate). Cell lysates were
obtained by centrifugation at 12,000 RPM for 15 min, and the
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Bicinchronoic Acid Assay kit (Pierce, Rockford, IL). Protein
lysates were prepared for SDS-PAGE by adding 1/4 volume of 46
SDS-PAGE sample buffer (100 mM Tris-Cl, pH 6.8, 200 mM
DTT, 4% SDS, 0.2% bromophenol blue, 20% glycerol) and
heating the mixture at 95uC for 5 min. Thirty micrograms of the
protein were separated via SDS-PAGE and transferred onto a
polyvinylidene difluoride membrane by electrophoresis (Immobi-
lon P; Millipore, Bedford, MA). After blocking with TBS Tween
buffer (10 Mm Tris-HCl, pH 8.0, 150 mM NaCl, 0.05% Tween-
20) containing 5% nonfat dry milk for 1 h at room temperature,
the membranes were incubated overnight at 4uC with blocking
solution containing the indicated antibody (diluted 1:1,000–
1:2,000). Membranes were washed and incubated with a suitable
HRP-conjugated secondary antibody (Cell Signaling Technology,
Danvers, MA). HRP activity was detected using an ECL kit
according to the manufacturer’s instructions (Pierce, Rockford, IL)
[21,23,24].
Quantitive RT-PCR
The relative expression levels of EZH2, Calponin, Cyclin D3
(CD3) and Cyclin-dependent kinase 2 (CDK2) were determined
by real time PCR analysis. Total mRNA was isolated using the
Trizol method and clean up was performed according to the
manufacters protocol using RNA easy kit from Qiagen. Equal
amounts of RNA were converted into cDNA using the iScript
cDNA synthesis kit (Bio-rad, Hercules, CA). Real-time PCR
downstream processing was performed on a Biorad cfx 96 real
time PCR system using specific primers to EZH2, Calponin, CD3
and CDK2 as shown below. All primers were purchased from
Integrated DNA Technologies. Inc (Coralville, IA) and reconsti-
tuted according to the manufacturer’s instructions. The final
concentrations of the primers used in the real time assays were
100 mM. Cq values were used to calculate the relative fold
difference in mRNA levels compared with the normalized
controls. All experiments were performed in triplicates. Primers
used were: EZH2 59- GCCAGACTGGGAAGAAATCTG-39
(forward), 59-TGTGCTGGAAAATCCAAGTCA-39 (Reverse);
Calponin 59-GGCATCATTCTTTGCGAATTC-39 (forward),
TGGTGATGGCCTTGATGAAG (Reverse); CDK2 -5 9- GCT
TTC TGC CAT TCT CAT CG -39(forward), 59- GTC CCC
AGA GTC CGA AAG AT -39 (Reverse); Cyclin D3 59- TGG
ATG CTG GAG GTA TGT G -39 (forward), 59- CGT GGT
CGG TGT AGA TGC -39(Reverse); and GADPH-59-CGGAGT-
CAACGGATTTGGTCGTAT-39 (forward), 59-AGCCTTCTC-
CATGGTGGTGAAGAC-39 (Reverse).
Chromatin Immunoprecipitation (ChIP) assay
The ChIP assay was performed on HPASMCs transfected with
either EZH2 or vector control using the EpiTect ChIP one day kit
(Qiagen, Valencia, CA) according to the manufacturer’s instruc-
tions. Cells (10
7) were fixed with formalin and sonicated after
neutralizing with glycine. Immunoprecipitaion was performed
using rabbit anti-tri-methyl histone (H3K27me3) antibody (Milli-
pore, Billerica, MA) or with normal rabbit IgG. DNA in the eluted
fractions were purified using spin columns provided in the kit and
subjected to PCR using the following primers designed to amplify
the promoter region of the calponin gene. (Calponin forward,
GGGTGAGATCTGGCTGGGTA calponin reverse,
GATCCTGGGTCTCACCCTCC). PCR using primers for
myogenic differentiation 1 (MYOD1) promoter (Qiagen, Valencia,
CA), a gene known to be regulated by histone methylation is used
as a positive control.
Statistical Analysis
All experiments were done in triplicates. A paired t-test was
used to determine the statistical significance. A p-value of p,0.05
was accepted as statistically significant.
Results
Increased expression of EZH2 in PASMCs was associated
with PAH progression in hypoxia-induced PAH mouse
model
An increased expression of EZH2 has been shown to correlate
with proliferation of cancer cells, but its relevance in PAH is not
known. To understand the relevance of EZH2 in PAH, mice were
exposed to hypoxic conditions for 6 weeks to induce PAH. RVSP
(mm Hg) and RV/LV+S were measured after 0, 3 and 6 weeks.
Mice exposed to hypoxic conditions showed time dependent
increase in RVSP and RV/LV+S indicating progression of PAH
as shown in Figure 1A and 1B. At the same time points, PASMCs
were isolated and proteins were probed for EZH2 as described in
Materials and Methods. EZH2 levels were increased in hypoxia-
induced PAH mice when compared to controls (Fig. 1C). These
results suggest that increased expression of EZH2 in mouse
PASMCs were associated with PAH progression in hypoxia-
induced PAH mouse model. The increase in EZH2 levels along
with the increase in PAH during hypoxia suggests an unidentified
potential role for this protein in PAH.
EZH2 expression is induced in proliferating HPASMCs
To identify the potential role of EZH2 in PASMCs proliferation
and PAH, we examined the expression of EZH2 in quiescent and
proliferative HPASMCs by using quantitative real-time PCR and
Western blot analysis. HPASMCs were treated with increasing
concentrations of FBS (1%, 5% and 10%) to stimulate prolifer-
ating conditions and levels of EZH2 were analyzed by both real-
time PCR and western blots. There was a 2 fold increase in EZH2
mRNA levels in proliferating HPASMCs in comparison to cells in
normal growth media with 5%FBS, while the levels reduced in
serum-starved PASMCs (Fig. 2A). A similar trend was also
observed at the protein level illustrated in Figure 2B. This indicates
that levels of EZH2 increases in response to proliferating
conditions in HPASMCs.
EZH2 overexpression induces proliferation of HPASMCs
The observation that EZH2 content was high in SMC under
proliferating conditions indicated that EZH2 could play a role in
SMC proliferation, as is suggested in some cancerous cells. The
role of EZH2 in HPASMCs proliferation was investigated by
transfecting HPASMCs with plasmids expressing EZH2. Positive
transfection was assessed by Western blotting and real-time PCR
for EZH2 mRNA (Fig. 3A). The transfected cells were fixed and
labeled with PI after 48 hrs and analyzed by flow cytometry to
determine proliferation. The percentage of cells in the G2/M
phase was significantly higher in EZH2-transfected cells in
comparison to mock-transfected cells (Fig. 3B). There was no
significant difference in the percentage of cells in the S-Phase of
the cell cycle. As the percentage of cells in G2/M phase indicates
proliferating cells, it can be inferred that the EZH2-transfected
cells have a 1.5 fold higher rate of proliferation when compared
with the control (mock-transfected) cells. Since there was an
increase in number of dividing cells in EZH2 transfected
HPASMCs, we further analyzed various proliferation markers
by real-time PCR in EZH2 and mock transfected cells. There was
an increase in CD3 and CDK-2 in EZH2 transfected cells
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cell cycle and increased proliferation in EZH2 transfected
HPASMCs. These findings support the hypothesis that EZH2
enhances HPASMCs proliferation.
EZH2 overexpression induces migration of HPASMCs
Vascular remodeling is a key feature of PAH and migration of
proliferating SMCs is considered an important event of this
remodeling process. The effect of EZH2 was assessed in migration
of the proliferating HPASMCs by wound healing assays (Fig. 4A).
There was a significant (p,0.001) increase in the wound healing in
EZH2-transfected HPASMCs when compared to GFP-transfected
controls (Fig. 4B) indicating that EZH2 not only enhances
proliferation but also increases its migratory potential thus
contributing to the pathogenesis of PAH.
EZH2 overexpression reduces apoptosis in HPASMCs
EZH2, apart from inducing cell proliferation, is also known to
reduce apoptosis. Hence apoptosis was assessed by Annexin-V
staining in HPASMCs transfected with EZH2 and in control
(mock-transfected) HPASMCs. The apoptotic and necrotic cells
could be differentiated by PI counter staining. EZH2 transfected
cells have a significantly higher percentage (p,0.005) of live cells
(64%), compared to the control group (23%) (Fig. 5), and
transfected cells showed a 2.5 fold reduction in apoptotic cells
when compared to mock-transfected cells (p,0.05). EZH2-
transfected cells displayed a significant decrease in the percentage
of cells in early and late apoptosis compared to control cells
(p,0.05) (Fig. 5). These findings show that EZH2 overexpression
leads to a significant decrease in apoptotic signaling in prolifer-
ating HPASMCs.
EZH2 overexpression modulates the HPASMC phenotype
Dedifferentiated SMCs demonstrate accelerated proliferative
phenotype that plays a critical role in PAH. Dedifferentiated
SMCs show suppressed expression of calponin, a contractile
phenotype marker. Calponin is a thin filament-associated protein
that apparently functions as a negative regulatory element for
SMC contraction. It may also have more broad cellular activities
independent of contractility [25]. Calponin levels increase almost
Figure 1. Increased expression of EZH2 in PASMCs was associated with PAH progression in hypoxia-induced PAH mouse model.
Five age and sex-matched C57BL/6 mice were exposed to room air (21% FiO2) or to hypoxia (10% FiO2) at sea level. Averaged (A) RVSP and (B) RV/
LV+S in mice at serial time points (0, 3 and 6 weeks) under hypoxic conditions of 10% oxygen (ten readings per mouse over 1 h, 20 mice per group at
each time point). (C) EZH2 protein expression by western blot at serial time points under hypoxic conditions of 10% oxygen. All experiments were
repeated at least 3 independent times
* P,0.05 compared with 0 hrs.
doi:10.1371/journal.pone.0037712.g001
Figure 2. EZH2 expression induced in proliferating HPASMCs.
HPASMCs were serum starved (1% FBS treated) or 10% serum treated
for 24 h, and then (A) EZH2 expression was detected by qRT–PCR. (B)
EZH2 protein expression was analyzed in serum-starved or 10% serum-
treated HPASMCs by Western blotting. All experiments were repeated
at least 3 independent times.
* P,0.05 compared with 5% FBS.
doi:10.1371/journal.pone.0037712.g002
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Hence, during the late embryo stage and in adult tissues, calponin
is used as a reliable marker for differentiated SMCs [25,27].The
established phenotypic and differentiation marker, calponin, was
measured to determine whether EZH2 affects the SMC pheno-
type. There was a significant (p,0.005) suppression of calponin
mRNA (Fig. 6A) and protein expression (Fig. 6B) in EZH2-
transfected HPASMCs when compared to vehicle-transfected
controls. These results indicate that EZH2 overexpression
modulates HPASMCs to a more proliferative synthetic phenotype.
The ChIP assays were performed in HPASMCs transfected with
EZH2 or vehicle control to determine if EZH2 was directly
suppressing calponin expression by histone trimethylation
(H3K27me3). PCR amplification of the promoter region for
calponin in ChIP assay with EZH2 transfected cells indicated that
EZH2 was directly down regulating calponin expression by
promoter compaction (Fig. 6C). These results indicate that
EZH2 over expression modulates HPASMCs to a more prolifer-
ative synthetic phenotype.
Discussion
PAH is a fatal disease caused by the obstruction of the small
pulmonary arteries by vascular proliferation and remodeling. It is
characterized by elevated pulmonary arterial pressures (PAP), and
increased pulmonary vascular resistance leading to right-sided
heart failure and death [1,7]. Evidence reveals that epigenetic
alterations may be involved in PAH such as changes in the
phenotype or in gene expression states, including chromatin
remodeling, DNA methylation and histone modifications [28].
The importance of EZH2 in the proliferation of HPASMCs and
its implications in the development of PAH is demonstrated for the
first time. EZH2 is a histone H3 lysine 27 methyltransferase of
polycomb-repressive complex 2 [29]. EZH2 transcriptionally
Figure 3. EZH2 overexpression induces proliferation of HPASMCs. HPASMCs were transfected with a plasmid expressing EZH2 or control
plasmids using 4D-Nucleofector system. A) EZH2 protein expression was analyzed by western blot (upper panel) and mRNA expression was analyzed
by real-time PCR (lower panel) to determine the transfection efficiency. B) The transfected cells were fixed and labeled with PI after 48 hrs and
analyzed for cell cycle by flow cytometry. Percentage number of cells in S and G2/M phase of the cell cycle is plotted (upper panel) and representative
histograms from the cell cycle analysis of EZH2 and control GFP plasmid transfected cells are shown (lower panel). C) Real-time PCR analysis of cell
proliferation markers expressed as normalized fold expression is shown. All experiments were repeated at least 3 times and graphs shown are
average of three independent experiments.
doi:10.1371/journal.pone.0037712.g003
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and cancer cells [30].
PAH and cancer cells share similar proliferating phenotypes
[31][32][33], and the overexpression of EZH2 is directly
responsible for the de novo suppression of multiple genes in
human cancer [14,29,30,34] and is a known pathogenic factor in
breast and prostate cancer [34]. An increased level of expression of
EZH2 in hypoxia-induced PAH mice is consistent with this
observation. Proliferating HPASMCs were also shown to have an
increased expression of EZH2 compared to non-proliferating
HPASMCs. Further studies on HPASMC-overexpressing EZH2
showed enhanced proliferation rates and confirmed the role of
EZH2 in HPASMC proliferation. This observation is consistent
with earlier observations in cancer cells suggesting a role for EZH2
in the control of proliferation in a variety of other normal,
immortalized and transformed cell types [14,30,34,35]. Vascular
remodeling is a key feature of PAH and several studies reported
that migration of proliferating vascular smooth muscles is an
important event in the remodeling process [4,6]. EZH2 knock-
down suppress the invasion and migration of human epithelial
ovarian cancer cells [15]. Consistent with this observation, the
wound healing assays done in this study suggest that EZH2
enhances the migratory capabilities of proliferating HPASMCs
thus playing a key role, not only in proliferation, but also in the
migration of HPASMCs. Our results also indicate that EZH2-
transfected HPASMCs are more resistant to apoptosis when
compared to mock-transfected controls. Consistent with this
observation is a report wherein EZH2 directly regulates the
apoptotic process in cancer cells through epigenetically modulat-
ing pro-apoptotic Bim expression [36].
SMCs are not terminally differentiated and possess the ability to
modulate their phenotype in response to external stimuli. SMCs
convert from a sessile, ‘‘contractile’’ phenotype to a motile,
proliferative ‘‘synthetic’’ phenotype during PAH [26,37]. This
change in phenotype is marked by a decrease in calponin, a SMC
phenotype marker [25]. To check the effects of EZH2 transfection
on the HPASMC phenotype, calponin levels were measured by
both real-time PCR and Western blot analysis. There is a decrease
in expression of calponin in EZH2 transfected cells indicating a
shift in the SMC phenotype from a contractile to more
proliferating one, which is a prominent feature of PAH. This
phenotypic modulation of SMC is accompanied by accelerated
migration and proliferation. However, at this point, we do not
Figure 4. EZH2 overexpression markedly increases cell migration in HPASMCs as measured by wound healing assay. The HPASMCs
were transfected with EZH2 and GFP plasmid or only with GFP plasmid (Control). An artificial wound was created using a 1 ml pipette on a confluent
monolayer of cells. A) Images were taken at 0 and 24 hrs after wound. B) Migration was quantified visually as the number of cells migrating in to the
gap and average of three experiments is plotted.
doi:10.1371/journal.pone.0037712.g004
Figure 5. EZH2 overexpression reduces apoptosis in HPASMCs.
HPASMCs cells were transfected with a plasmid expressing EZH2 or with
GFP using 4D-Nucleofector system. Apoptosis was measured in
transfected cells by using Annexin V staining. Propidium iodide (PI)
incorporation was measured by flow cytometry to assess the mode of
cell death. Relative fluorescence units represent the intensity of annexin
V incorporation and PI incorporation was quantified. The noted
experiments are representative of a minimum of four similar
evaluations.
* P,0.05 compared with control.
doi:10.1371/journal.pone.0037712.g005
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expression. Over-expression of calponin in cultured SMCs
suppresses their proliferation [38]. However, the definitive role
of this molecule in SMCs proliferation is unclear. Therefore, it is
important to understand whether EZH2 directly modulates
calponin levels to drive SMCs to a more proliferative phenotype
or whether its reduction of calponin is a result of de-differentiation
of SMCs. ChIP assays were performed in HPASMCs over
expressing EZH2 and for the first our results show that calponin is
regulated by histone methylation by EZH2 in HPASMCs.
The fundamental mechanism of PAH is suggested to evolve
from an imbalance between proliferation and anti-proliferation of
PASMCs [2,6]. However, the underlying causes or genetic factors
responsible for this imbalance are not clear. This report indicates
that EZH2 modulates proliferation, migration and apoptosis in
HPASMCs and is increased in hypoxia-induced PAH. The
molecular mechanisms of the modulation of these functions by
EZH2 are not clear and a detailed study is warranted to further
elucidate the importance of EZH2 in vascular smooth muscle cell
function and in the development of PAH. This may help to
develop new therapeutic targets to treat PAH.
In conclusion, EZH2 appears to be a key regulator of the
PASMC function in the pulmonary vasculature. Elevated levels of
EZH2 facilitate the proliferation and migration of PASMCs and
enhance their resistance to apoptosis, leading to the thickening of
the medial layer of pulmonary artery. These results suggest that
EZH2 is a potent regulator of PASMC and a disturbance in its
expression levels can lead to the development of PAH.
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